• [[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

    laureng Whitepapers April 19, 2018
  • [[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

    laureng Whitepapers April 19, 2018
  • Choosing the Right Channel Strategy for Specialty Product Success

    Karina Kusova Clinical Development, Market Access, Orphan Drug Congress, Supply Chain & Manufacturing, Uncategorized, Whitepapers May 3, 2017
  • [Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

    Karina Kusova Clinical Development, Orphan Drug Congress, Uncategorized, Whitepapers April 10, 2017
  • [[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

    Karina Kusova Clinical Development, Featured on App, Orphan Drug Congress, Uncategorized, Whitepapers April 6, 2017
  • What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

    Karina Kusova Advocacy, Clinical Development, Market Access, Orphan Drug Congress, Orphan Drugs Live October 10, 2016

Subscribe to Total Orphan Drugs

Strategy and innovation in the orphan drugs and rare diseases industry
Navigation
  • Development
  • Regulation
  • Advocacy
  • Market Access
  • Partnering & Investment
  • Whitepapers
  • Events
    • USA
  • Search
non-G551D

Tag Archive

View Post

Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations

In Press Release by CameronJune 30, 2014Leave a Comment

In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- KALYDECO is the first medicine to treat the underlying …

Categories

  • Advocacy
  • Clinical Development
  • Featured on App
  • Market Access
  • Orphan Drug Congress
  • Orphan Drugs Live
  • Partnering & Investment
  • Press Release
  • Regulation & Government
  • Reports
  • Supply Chain & Manufacturing
  • Uncategorized
  • Whitepapers
Toggle the Widgetbar
World Orphan Drug Congress USA
  • Home
  • About Us/Advertise